Article
Detecting Secondary C-KIT Mutations in the Peripheral Blood of Patients with Imatinib-Resistant Gastrointestinal Stromal Tumor.
Oncology - 1 Jan 2016
Wada Noriko, Kurokawa Yukinori, Takahashi Tsuyoshi, Hamakawa Takuya, Hirota Seiichi, Naka Tetsuji, Miyazaki Yasuhiro, Makino Tomoki, Yamasaki Makoto, Nakajima Kiyokazu, Takiguchi Shuji, Mori Masaki, Doki Yuichiro
Abstract excerpt
OBJECTIVE: Imatinib is a standard treatment for metastatic gastrointestinal stromal tumor (GIST). Imatinib resistance is mostly caused by secondary mutations in C-KIT. The antitumor effect of second-line agents is correlated with the type of secondary mutation: indeed, sunitinib is effective against tumors with C-KIT exon 13 or 14 mutations. We investigated whether secondary C-KIT mutations can be detected in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.